Home / Press Release / Global Pulmonary Arterial Hypertension (PAH) Treatment Market Expected To Reach US$ 14,642.1 Mn By 2026

Global Pulmonary Arterial Hypertension (PAH) Treatment Market Expected To Reach US$ 14,642.1 Mn By 2026

The latest market report published by Credence Research, Inc. “Pulmonary Arterial Hypertension (PAH) Treatment Market Growth, Future Prospects, and Competitive Analysis, 2018–2026” the pulmonary arterial hypertension treatment market was valued at US$ 7,802.9 Mn in 2017 and projected to reach US$ 14,642.1 Mn by 2026 at a CAGR of 7.6% over the forecast period from 2018 to 2026.

Browse the full report Pulmonary Arterial Hypertension (PAH) Treatment Market Growth, Future Prospects, and Competitive Analysis, 2018–2026 at  https://www.credenceresearch.com/report/pulmonary-arterial-hypertension-pah-treatment-market

Market Insights

The pulmonary arterial hypertension (PAH) treatment market is expected to exhibit a remarkable CAGR during the forecast period from 2018 to 2026. PAH is a rare, progressive disorder characterized by high blood pressure in the arteries that go from heart to the lungs. Drivers accountable for the market growth are globally growing older population coupled with mounting prevalence of PAH due to causative diseases including lung diseases, human immunodeficiency virus (HIV) infection, connective tissue disorders, chronic liver diseases, sedentary lifestyle, and other idiopathic conditions. Moreover, increasing launches of innovative drugs & treatment therapies, favorable initiatives by various governments, and rising spending over healthcare is supporting the market growth. The European Respiratory Society (ERS) reported that the worldwide prevalence of PAH is ranging from 10 to 52 cases per million and estimated to be in the range of 100,000–200,000 every year. The presence of favorable government support in the U.S. such as Orphan Drug Act (ODA) 1983 and the Rare Disease Act (RDA) of 2002 to facilitate the development of orphan drugs with benefits including tax incentives (reduced taxes/tax credits equal to half of the development costs), clinical research subsidies, and improved patent protection & marketing rights. In addition, RDA amended to create a centralized structure (statutory authorization) for coordinating the research or recommend national research agendas in order to better facilitate the research & education.

The market dynamics would be varying by the end of 2020 as some of the blockbuster PAH treatment drugs such as Tracleer (bosentan), Adcirca, Letairis, and Tyvaso will go off-patent after 2018 and the entry of generic drugs with reduced prices than patented drugs would get facilitated.

Key Market Movements:

Contact Information
24/7 Research Support
Phone: +1-800-361-8290
sales@credenceresearch.com
Get in Touch with us
Join us on Facebook
Follow us on Twitter
Join us on LinkedIn
Add us on Google +